RA Capital Boosts Wave Stake Amid Clinical Setback
🚨Here is an interesting report from this week’s @barronsonline regarding a major investment made in $WVE by RA Capital - despite Wave’s recent disappointing clinical readout of its obesity candidate $WVE-007 🧵👇. According to the report RA Capital has raised its stake in the Wave to 34,225,506 shares by purchasing an additional 8,772,496 of Wave Life Sciences shares - from March 26 through March 30, at a share price which ranged from $5.37 to $6.74. Following the latest purchases, RA Capital owns a 17.5% stake in Wave Life Sciences’ outstanding stock which have lost ~ 56.7% of their value in 2026. Interesting. $XBI
BeamTx's Risto‑cel Shows Promising Phase
1/@BeamTx announced the publication of clinical data from its Phase 1/2 BEACON clinical trial evaluating risto-cel - formerly known as $BEAM-101 for the treatment of sickle cell disease (SCD). The data was presented at #ASH25 🧵👇 & was published in...
FDA Grants RMAT Status to Caribou’s Anti‑BCMA CAR‑T Therapy
1/🚨@CaribouBio announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 - $CRBU allogeneic anti-BCMA CAR-T Cell Therapy for treating relapsed or refractory multiple myeloma (r/r MM) cancer which is being evaluated in the CaMMouflage...
Biogen Buys Apellis for $5.6B, Adds SYFOVRE Sales‑linked CVR
1/Another mega M&A deal in the BioTech and Pharma sector with the acquisition of Apellis Pharmaceuticals - $APLS by Biogen $BIIB for $41 per share in cash at closing in a $5.6B deal. In addition, Apellis stockholders will also receive...
Gates Foundation Funds TesseraTx's Gene‑editing HIV Cure Research
1/🚨@TesseraTx has announced that it has received a grant from the Gates Foundation to fund an early-stage research which is aimed to develop a Gene Editing-based cure for HIV. This grant is build upon Tessera’s existing investment 🧵👇 from the Gates...
Weekly Biotech Roundup: Top Posts Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
Elon Musk Shows True Leadership by Reversing Policy
Kudos to @elonmusk and @nikitabier for reviewing their decision🧵👇. When people make fun of my admiration for Elon Musk - here is example No. 203,321 as to why I think Elon is the greatest business leader of our lifetime. Elon’s...
X’s Regional Silencing Threatens Global Biotech Community
One major issue in 𝕏’s new regional silencing policy 🧵👇is that it will destroy many of the professional communities on 𝕏. Here is a relevant example for @nikitabier and @elonmusk - the BioTech community on 𝕏 includes many scientists, investors,...
Weekly Biotech Roundup: Top Insights Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Eli Lilly Surges to #1 Pharma Sales in 2025
Another testimony of Eli Lilly’s increasing dominance in the BioTech and Pharma sector - compared to other Big Pharma companies - such as $PFE $JNJ $NVS $NVO $BMY $ABBV $MRK $SNY and others, can be seen in this excellent @NatRevDrugDisc...
Japan Leads Stem Cell Revolution Since Yamanaka’s 2006 Breakthrough
Not many are aware but Japan 🇯🇵 is a true powerhouse when it comes to Stem Cells research & the field of regenerative medicine since 2006 - when stem-cell biologist Shinya Yamanaka, working at Japan’s @KyotoU_News identified a handful of...
Weekly Biotech Roundup: Top Tweets Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
BBC Infographic Explains UniQure Gene Therapy for Huntington
Especially after the recent disappointing regulatory update regarding $QURE AMT-130 clinical candidate for treating Huntington disease and the FDA refusal to move forward 🧵👇- here is an excellent Infograph by the BBC which explains how exactly the mechanism of @uniQure_NV’s...
FDA Grants Fast Track, Orphan Status to TSRA-196
1/@TesseraTx has announced that the U.S. FDA has granted Fast Track and Orphan Drug designations to TSRA-196 - its leading In Vivo Gene Editing program which is being jointly developed with $REGN, for the treatment of patients with alpha-1 antitrypsin deficiency...
Weekly BioTech Roundup: Top Posts Curated by BiopharmIQ
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
FDA Cracks Down as Novo Sues Hims over Semaglutide
This is the first reference which I heard directly from FDA commissioner Dr. Marty Makary regarding $HIMS, $NVO 🧵👇and the recent legal actions that the HHS had initiated against HIMs and Hers. When he was asked by @annikakimc - @CNBC’s...
Must‑Follow BioTech & Finance Accounts for Creators
Part of being a content creator on 𝕏 should be to promote other valuable creators as much as possible. So, here is a list of top tier accounts who create exceptional content & who are A MUST FOLLOW in BioTech...
CRISPRTX Unveils 2026 Roadmap: In‑Vivo
1/@CRISPRTX recent #JPM26 presentation emphasised the company’s strategic priorities and planned milestones for 2026. Here’s my 🧵👇which focuses on CRISPR’s In-Vivo and siRNA extended pipeline, the progress of CASGEVY’s launch and $CRSP current corporate status. $XBI #JPM2026 https://t.co/octkTAE5h4
Top JPM26 Highlights: Weekly BioTech Recap
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ, which is a comprehensive recap of the past week in BioTech. This time he gathered the best posts - written by some of the brightest BioX accounts, about...
BiotechCH's Space: Must‑Watch for BioTech & Pharma Enthusiasts
I highly recommend attending @BiotechCH’s upcoming space today - which in my opinion is the most interesting space on 𝕏 for those interested in BioTech, Pharma, Life Sciences & everything in between….If you can’t attend it’s also available on the...
Poll: Which Company Should I Thread Next?
So far I have finished writing two comprehensive 🧵which covered both $BEAM & $PRME #JPM26’s presentations. $XBI Before I continue to write additional #JPM2026🧵’s I’m interested in hearing your thoughts about which company - if at all - would you want...
BeamTx Unveils 2026 Roadmap and FDA Wins
1/@BeamTx’s #JPM26 excellent presentation emphasised its strategic priorities & future milestones for 2026. Here’s my🧵👇which elaborates on BEAM’s current pipeline, the regulatory breakthroughs that $BEAM has managed to negotiate with the FDA & its corporate status $XBI #JPM2026 https://t.co/kK7Q1YVjOV
Why JPM2026 Is the Must‑Watch BioTech Event
As we are heading into the most important week in the BioTech & Pharma sector - #JPM2026 - here is an excellent 🧵👇by @statnews’ @adamfeuerstein which explains - to those less familiar, what is exactly #JPM26 & why it is...
Europe Pharma R&D Lags, Companies Flee to U.S.
1/🚨Here is another great article - by FT excellent global Pharma correspondent @aanuadeoye, which wonderfully describes the rapid decline of the European 🇪🇺 and British 🇬🇧 Biotech and Pharma ecosystem and the growing gap between them and the American 🇺🇸...